NASH/MASH Treatment Market: Explosive Growth from $178M In 2024 To $16.82B By 2033

The Global NASH/MASH Treatment Market reached US$ 7.87 billion in 2024 and is expected to reach US$ 31.76 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033. The approved drugs market value is reported at US$ 178.31 million in 2024 and is expected to reach US$ 16.82 billion in 2033 growing at a CAGR of 57.05%.

The NASH/MASH Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with the knowledge needed to make strategic decisions and maintain a competitive advantage. Utilizing a blend of qualitative and quantitative research methodologies, the firm delivers in-depth reports that support clients in understanding complex market dynamics, fostering strategic development, and capturing new opportunities in today's rapidly changing global environment.

Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/nash-or-mash-treatment-market?kb

Evolving Market Forces and Opportunities:

NASH (Nonalcoholic Steatohepatitis), now widely referred to as MASH (Metabolic dysfunction-associated steatohepatitis), is a progressive liver disease characterized by inflammation and liver cell damage, along with fat accumulation in the liver. It is a more severe form of NAFLD (Nonalcoholic Fatty Liver Disease) and can lead to fibrosis, cirrhosis, and liver failure. MASH is strongly associated with obesity, type 2 diabetes, insulin resistance, and metabolic syndrome.

Key Industry Players Driving the NASH/MASH Market:

Madrigal Pharmaceuticals. The emerging players include Novo Nordisk A/S, Boehringer Ingelheim International GmbH., 89bio, Inc., Inventiva., CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD, Sagimet Biosciences., and Akero Therapeutics, Inc. among others.

Industry Development:

In March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), marking it as the first therapy specifically indicated for adult MASH patients with moderate to advanced liver fibrosis (F2-F3). Developed by Madrigal Pharmaceuticals, Inc., Rezdiffra is a once-daily oral THR-β agonist that demonstrated strong safety and efficacy in the Phase 3 MAESTRO-NASH trial.

In October 2024, survodutide, a GLP-1 receptor agonist developed by Boehringer Ingelheim International GmbH, was granted Breakthrough Therapy designation by the U.S. FDA for the treatment of adult MASH patients with F2-F3 stage fibrosis, highlighting its potential to address a major unmet need in metabolic liver disease.

Research Methodology:

Both primary and secondary data sources have been used in the global NASH/MASH Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/nash-or-mash-treatment-market?kb

Segment Covered in the NASH/MASH Market:

By Drug: Resmetirom (Rezdiffra), Lanifibranor, Semaglutide, Survodutide, Pegozafermin, Efruxifermin, Denifanstat, Others

By Stage: Stage 0-1, Stage 2-3, Stage 4

By Age-Group: Pediatrics, Adults, Geriatrics

By Gender: Male, Female

Regional Overview for NASH/MASH Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/nash-or-mash-treatment-market?kb

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the NASH/MASH market?

➠ Who are the leading manufacturers in the global NASH/MASH industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global NASH/MASH industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the NASH/MASH market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.